Pneumothorax during Alectinib Treatment for a Uterine Inflammatory Myofibroblastic Tumor with Lung Metastasis

• Published in: Journal of cancer research and practice Vol. 10; no. 2; pp. 71 - 74
• Main Authors: Lin, Chang-Ting, Wu, Chen-Hsuan, Huang, Hsuan-Ying, Liu, Chien-Ting
• Format: Journal Article
• Language: English
• Published: India Medknow Publications & Media Pvt Ltd 01.04.2023; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer Medknow Publications
• Edition: 2
• Subjects: alectinib; Antimitotic agents; Antineoplastic agents; Cancer; Care and treatment; Case Report; Chemotherapy; Diagnosis; inflammatory myofibroblastic tumor; Metastasis; Non-Hodgkin's lymphomas; Pneumothorax; Sarcoma; Taiwan; Alectinib; inflammatory myofibroblastic tumor; pneumothorax
• ISSN: 2311-3006; 2311-3006
• DOI: 10.4103/ejcrp.eJCRP-D-22-00031

An inflammatory myofibroblastic tumor (IMT) is an uncommon sarcoma subtype with histopathological features, including inflammatory infiltrates. Anaplastic lymphoma kinase (ALK) gene rearrangement has been reported in half of the patients with IMTs; therefore, crizotinib, an ALK inhibitor, may achieve a response rate of 50% in these patients. We present a case with an initial diagnosis of uterine sarcoma and multiple lung metastases. After the failure of doxorubicin-based chemotherapy, revised pathology from a palliative hysterectomy revealed an IMT with ALK gene rearrangement. Treatment with alectinib achieved an excellent tumor response. The accurate differential diagnosis of uncommon sarcoma subtypes is crucial because a specific targeted therapy may considerably alter treatment outcomes.